Wedbush Lifts Earnings Estimates for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Wedbush increased their Q1 2025 earnings estimates for Neurocrine Biosciences in a research report issued on Monday, December 23rd. Wedbush analyst L. Chico now expects that the company will earn $1.52 per share for the quarter, up from their previous estimate of $1.49. Wedbush has a “Outperform” rating and a $148.00 price target on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.94 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.82 EPS, Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.46 EPS, FY2025 earnings at $7.71 EPS and FY2026 earnings at $10.87 EPS.

Several other equities analysts have also weighed in on the company. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research note on Monday. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. Finally, Royal Bank of Canada dropped their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $166.29.

Neurocrine Biosciences Trading Down 0.3 %

Shares of Neurocrine Biosciences stock opened at $136.53 on Tuesday. The stock has a market capitalization of $13.82 billion, a P/E ratio of 36.60 and a beta of 0.34. The business’s fifty day moving average price is $124.40 and its 200 day moving average price is $130.59. Neurocrine Biosciences has a twelve month low of $110.95 and a twelve month high of $157.98.

Insider Buying and Selling

In other news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now directly owns 2,507 shares in the company, valued at $338,445. This trade represents a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences in the second quarter valued at $28,000. Innealta Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth $30,000. Blue Trust Inc. lifted its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. Plato Investment Management Ltd boosted its position in shares of Neurocrine Biosciences by 44.1% in the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after purchasing an additional 130 shares during the period. Finally, Truvestments Capital LLC purchased a new position in Neurocrine Biosciences in the 3rd quarter worth about $63,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.